<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.2minutemedicine.com/feed/</title><link>https://www.2minutemedicine.com/feed/</link><description>Individual feed output.</description><lastBuildDate>Thu, 15 Jan 2026 16:02:38 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients</title><link>https://www.2minutemedicine.com/yartemlea-narsoplimab-wuug-improves-platelets-hemolysis-organ-function-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-transplant-patients/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2014/12/Human_embryonic_stem_cells-300x150.png</image_url><description>1. Yartemlea (narsoplimab-wuug) is the first on‑label complement inhibitor for hematopoietic stem cell transplant (HSCT) associated thrombotic microan...</description><pubDate>Thu, 15 Jan 2026 18:48:46 GMT</pubDate></item><item><title>FDA highlights flexible chemistry manufacturing controls expectations for cell and gene therapies</title><link>https://www.2minutemedicine.com/fda-highlights-flexible-chemistry-manufacturing-controls-expectations-for-cell-and-gene-therapies/</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture4.png</image_url><description>1. New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, in...</description><pubDate>Thu, 15 Jan 2026 15:20:39 GMT</pubDate></item><item><title>One in three people with cystic fibrosis may experience nephrolithiasis during their life</title><link>https://www.2minutemedicine.com/one-in-three-people-with-cystic-fibrosis-may-experience-nephrolithiasis-during-their-life/</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture10.png</image_url><description>1. Nearly one in three people with cystic fibrosis experienced nephrolithiasis during their lifetime. 2. The degree of exocrine pancreatic insufficien...</description><pubDate>Thu, 15 Jan 2026 00:00:14 GMT</pubDate></item><item><title>Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates</title><link>https://www.2minutemedicine.com/nuzolvence-zoliflodacin-first-oral-gonorrhea-treatment-shows-non-inferior-cure-rates/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2014/09/gonorrhea-e1411353243851-300x150.jpg</image_url><description>1. Nuzolvence (zoliflodacin) is the first single‑dose oral agent for uncomplicated urogenital gonorrhea, showing non‑inferior cure rates to ceftriaxon...</description><pubDate>Wed, 14 Jan 2026 19:40:43 GMT</pubDate></item><item><title>Brain-penetrant enzyme replacement therapy improves biomarkers in mucopolysaccharidosis type II</title><link>https://www.2minutemedicine.com/brain-penetrant-enzyme-replacement-therapy-improves-biomarkers-in-mucopolysaccharidosis-type-ii/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2014/11/FMRI_Brain_Scan-e1421476109965.jpg</image_url><description>1. In this open-label phase 1–2 study, pediatric patients with mucopolysaccharidosis type II treated with tividenofusp alfa showed substantial reducti...</description><pubDate>Wed, 14 Jan 2026 16:00:29 GMT</pubDate></item></channel></rss>